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Abstract
Introduction The mainstay of management for locally
advanced rectal cancer is chemoradiotherapy followed
by surgical resection. Following chemoradiotherapy, a
complete response may be detected clinically and radio-
logically (cCR) prior to surgery or pathologically after
surgery (pCR). We aim to report the overall complete
pathological response (pCR) rate and the reliability of
detecting a cCR by conventional pre-operative imaging.
Methods A pre-planned analysis of the European Society
of Coloproctology (ESCP) 2017 audit was performed.
Patients treated by elective rectal resection were included.
A pCR was defined as a ypT0 N0 EMVI negative primary
tumour; a partial response represented any regression
from baseline staging following chemoradiotherapy. The
primary endpoint was the pCR rate. The secondary end-
point was agreement between post-treatment MRI
restaging (yMRI) and final pathological staging.
Results Of 2572 patients undergoing rectal cancer sur-
gery in 277 participating centres across 44 countries,
673 (26.2%) underwent chemoradiotherapy and sur-
gery. The pCR rate was 10.3% (67/649), with a partial
response in 35.9% (233/649) patients. Comparison of
AJCC stage determined by post-treatment yMRI with
final pathology showed understaging in 13% (55/429)
and overstaging in 34% (148/429). Agreement between
yMRI and final pathology for T-stage, N-stage, or
AJCC status were each graded as ‘fair’ only (n = 429,
Kappa 0.25, 0.26 and 0.35 respectively).
Conclusion The reported pCR rate of 10% highlights
the potential for non-operative management in selected
cases. The limited strength of agreement between basic
conventional post-chemoradiotherapy imaging assess-
ment techniques and pathology suggest alternative
markers of response should be considered, in the con-
text of controlled clinical trials.
Keywords Rectal surgery, rectal cancer, pathology,
radiology, neoadjuvant therapy, surgical oncology,
deferral of surgery
What does this paper add to the literature?
This paper highlights the potential for selective non-
operative management of rectal cancer with long-course
chemoradiotherapy. We report a complete pathological
response rate of 10.3% in an international audit. There
was limited agreement between basic conventional post-
chemoradiotherapy imaging and pathological staging,
demonstrating a need for better use of current markers
or more sensitive markers of treatment response.
Introduction
Approximately 450 000 rectal cancers are diagnosed
worldwide annually [1]. In developed countries, in
which 55% of these diagnoses are made, 45–55% of
electively managed patients will receive chemoradiother-
apy prior to the cancer resection [2]. The surgical resec-
tion, performed according to the principles of total
mesorectal excision (TME), is widely regarded as the
mainstay of curative treatment for resectable rectal can-
cer [3]. However, rectal cancer resections have signifi-
cant morbidity along with a 90-day mortality of
approximately 4–5% [2,4]. Furthermore, the long-term
consequences of treatment of pre-operative radiotherapy
and surgery can profoundly impair quality of life, this
may be attributed to bowel dysfunction following a
restorative procedure [5,6], living with the challenges
and complications of a permanent stoma [7], or geni-
tourinary side effects of treatment [8].
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Over the past decade there has been increasing inter-
est in avoiding the consequences of a TME procedure
through organ preserving approaches [9,10]. This is on
the proviso that equivalent or favourable oncological
outcomes can be achieved with a lower overall morbid-
ity. One approach has been to consider deferral of sur-
gery, whereby patients who have responded favourably
to pre-operative chemoradiotherapy do not undergo
surgery if there is no evidence of detectable tumour by
clinical, endoscopic and radiological surveillance. These
patients are diagnosed with a clinical complete response
(cCR), this approach is also termed “Watch and Wait”
or ‘Non-Operative Management’ [11,12].
The original Watch and Wait concept was based on
the observation of no residual tumour cells (a pathologi-
cal complete response (pCR)) in up to 26.8% of rectal
cancer specimens following chemoradiotherapy [10]. Fur-
thermore, with optimal follow-up, selected patients who
participate in these programmes were reported to have
favourable oncological outcomes compared with patients
who underwent surgery, with 5-year disease-free and
overall survival exceeding 90% [10]. Deferral of surgery is
increasingly reported as a feasible approach for rectal can-
cer management, with acceptable detection rates of
regrowth and safe surgical salvage [13,14]. A meta-analy-
sis of 17 studies, from centres with established surveil-
lance protocols for deferral of surgery, reported a clinical
complete response rate (cCR) of 22.4% (95% CI:14.3–
31.8) [15]. However most of these centres pursue strate-
gies thought to enhance the likelihood of a favourable
response, including consolidation or induction
chemotherapy sensitizing regimes [16] radiotherapy dose
escalation of up to 66 Gy [17] and offering chemoradio-
therapy to smaller tumours (over 25% of the tumours in
the meta-analysis were cT2 or less) [15].
The aim of this study was to record the complete
pathological response rate reported in a ‘real world’ set-
ting in order to determine the potential for widespread
uptake of non-operative rectal cancer management. We
also aimed to determine whether conventional radiolog-
ical assessment of response to chemoradiotherapy is suf-
ficiently reliable to feasibly consider generalised
implementation of non-operative management in cur-
rent clinical practice.
Methods
Protocol
This prospective, observational, multi-centre study was
conducted in line with a pre-specified protocol (http://
www.escp.eu.com/research/cohort-studies). An exter-
nal pilot of the protocol and data capture system was
conducted in five international centres prior to launch,
allowing refinement of the study tool and delivery.
This data was not included within the main study
analysis.
Centre eligibility
Any unit performing gastrointestinal surgery was eligible
to register to enter patients into the study. No mini-
mum case volume, or centre-specific limitations were
applied. The study protocol was disseminated to regis-
tered members European Society of Coloproctology
(ESCP), and through national surgical or colorectal
societies. Units recruiting patients to rectal cancer trials
were still eligible to participate in the study.
Patient eligibility
Adult patients (≥ 16 years) undergoing elective
resection for rectal cancer treated with long-course
pre-operative chemoradiotherapy, with or without meta-
static disease, were extracted from the main audit data-
base. A rectal cancer was defined as an adenocarcinoma
0–15 cm from the anal verge on rigid sigmoidoscopy or
MRI. Concomitant chemoradiotherapy was a manda-
tory inclusion criteria, however the dose of chemother-
apy and the delivery of long-course radiotherapy was
administered to according to unit and clinician prefer-
ence. Patients undergoing palliative pre-operative ther-
apy, chemotherapy alone or short course radiotherapy
were excluded.
Data capture
Consecutive sampling was performed for eligible
patients over an 8-week study period in each included
centre. Local investigators commenced data collection
on any date between the 1 February 2017 and 15
March 2017, with the last eligible patient being
enrolled on 10 May 2017. Small teams of up to five
surgeons or surgical trainees worked together to collect
prospective data on all eligible patients at each centre.
Quality assurance was provided by at least one consul-
tant or attending-level surgeon. Data was recorded con-
temporaneously and stored on a secure, user-encrypted
online platform (REDCap) without using patient identi-
fiable information. Centres were asked to validate that
all eligible patients during the study period had been
entered, and to attain > 95% completeness of data field
entry prior to final submission.
Demographic data including Age, Gender, American
Society of Anaesthesiologists (ASA) classification grade,
smoking history, body mass index, cardiovascular
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disease, indication for surgery and disease location. The
index operation, operative steps, approach, duration and
morbidity were recorded. Tumour staging information
(T-stage, N-stage, extramural vascular invasion),
recorded at three different timepoints, were available: 1.
Baseline pre-neoadjuvant treatment MRI staging; 2.
Post-treatment MRI staging; 3. Post-treatment patho-
logical staging. Staging was summarised according to
IUCC/AJCC TNM 7 system [18]. The MRI Rectum
was performed according to individual unit protocol.
An MRI for baseline staging was mandatory for all rec-
tal cancers included in the study, the post treatment
MRI was encouraged but was not compulsory. A com-
plete pathological response (pCR) has been defined pre-
viously as ypT0,N0 [19], our definition also required
the ypEMVI status to be negative. Tumor regression
was staged into three categories: a complete pathologi-
cal response (no visible cancer cells), a partial response
(regression from baseline MRI to pathology for one or
more of T stage, N stage, EMVI status), and no
change/progression from the baseline MRI staging.
The circumferential rectal margin (CRM) was regarded
as involved if the microscopic tumor extension reached
≤ 1 mm from the margin. Central quality control of
surgical specimens by pathologic examination was not
performed.
Outcome measures
The primary outcome measure was the rate of complete
pathological response. The secondary outcome measure
was the concordance of the TNM-based post-treatment
MRI assessment and post-treatment pathological stag-
ing for T stage, N stage and overall AJCC TNM grade,
assessed using Kappa agreement and the Intraclass Cor-
relation Coefficient.
Statistical analysis
This report has been prepared in accordance to guideli-
nes set by the STROBE (strengthening the reporting of
observational studies in epidemiology) statement for
observational studies [20]. Patient, disease and operative
characteristics were compared using descriptive analysis
and tests of normality were used to guide analysis.
Chi-squared test was used for categorical data, Stu-
dent’s t-test for normally distributed continuous data
and Mann-Whitney U test for non-parametric data. To
explore associations between T-stage, nodal status,
EMVI status and tumour height with pathological com-
plete response univariable logistic regression models
were fitted, described as odds ratios with 95% confi-
dence intervals.
The reliability of post-treatment MRI restaging to
assess response to neoadjuvant therapy was assessed by
the Kappa agreement between the post-treatment MRI
and pathology T-, N- and AJCC-staging [21]. A Kappa
value of < 0.20 was interpreted as ‘Poor’, 0.21–0.40 as
‘Fair’, 0.41–0.60 as ‘Moderate’, 0.61–0.80 as ‘Good’,
and 0.81–1.00 as ‘Very good’. An estimate of the Intra-
class Correlation Coefficient was also reported, with
95% exact confidence intervals (95% CI) derived using
the variance components from a one-way ANOVA
[22,23]. Data analysis was undertaken using R Studio
V3.1.1 (R Foundation, Boston, MA, USA).
Ethical approval
All participating centres were responsible for compliance
to local approval requirements for ethics approval or
indemnity as required. In the UK, the National Research
Ethics Service tool recommended that this project was
not classified as research, and the protocol was registered
as clinical audit in all participating centres.
Results
Figure 1 shows inclusion of patients within this study.
A total of 2572 patients underwent surgery for rectal
cancer in 277 participating centres across 44 countries.
Of these, 673 (26.2%) underwent CRT and TME sur-
gery. Twenty four patients were excluded due to miss-
ing MRI or pathology staging. The median (IQR) age
of the remaining 649 patients was 65 years (56–
71 years). 35% (229/649) were female.
pCR was reported in 10.3% (67/649) patients. An
overall partial response occurred in 35.9% (233/649),
with T stage regression in 42.8% (278/649), N stage
regression in 71.6% of those with baseline node positiv-
ity (111/155), and EMVI regression in 82.5% with
baseline mrEMVI positivity (33/40). No regression
occurred in 53.8% (349/649) patients. Treatment fail-
ure with progression of T-staging was seen in 9.4%
(53/562), N-staging in 8.9% (52/583) and EMVI-sta-
tus in 17.6% (99/561).
Demographic and operative data are compared
according to tumour response in Table 1. Overall the
mean (SD) tumour height was 4.1 cm [1.9], whereas
the pCR group were significantly closer to the anal
verge (mean (SD) 3.2 cm [1.7], P < 0.007). Patients
with a pCR were more likely to undergo a restorative
resection 73.1% (P = 0.004) and a significantly higher
proportion of robotic cases were performed on patients
with a pCR (27%[13/48], P < 0.001) compared with
11.4% [38/333] and 6.0% [16/268] for laparoscopic
and open approaches, respectively. Response was not
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influenced by age, gender and patient fitness in this ser-
ies. The degree of regression did not influence Clavien
Dindo reported complication rates.
Baseline MRI staging (n = 649), post-CRT MRI
staging (n = 429), and pathological staging are com-
pared against tumour response in Table 2. A post-treat-
ment MRI was performed in 66.1% (429/649) of
patients. According to the baseline MRI over 70% of
tumours were T3 in all response groups, only 4.5%
of pCR tumours were mrT4 and the highest proportion
of T4 tumours were in the partial response group
23.6% (55/233). mrT1 were reported in 8 (1.2%) cases,
these were mrEMVI or mrN2 +ve tumours and all
patients were non-responders. Following CRT, ymrT1
was reported in 7.7% overall and in 20% of pCR group.
Figure 2 displays response rates by tumour height and
pre-treatment MRI T-stage. Complete response was
more common in T1/T2 tumours than T3/T4
Records uploaded to the ESCP 
REDCap database (n=5788) 
Excluded from analysis (n=147)
•  Patients <16 years (n=2)
•  Missing anastomosis type (n=49)
•  Missing anastomotic leak outcome (n= 65)
•  Missing complication outcome (n=31)
Patients undergoing rectal surgery (n=3079) 
Patients undergoing elective surgery (n=4487)
Excluded from analysis (n=1408) 
♦  Patient undergoing resection involving the colon 
only (n=1398) 
♦  Missing (n=10) 
Excluded from analysis (n=1154) 
♦  Emergency surgery (less than 24h) (n=591) 
♦  Expedited surgery (less than 2 weeks) (n=563) 
Eligible and completed records (n=5641) 
Enrollment 
Data cleaning
Cohort selection 
Elective rectal cancer resection with long course CRT (n=649) 
•  Pathological Complete Response (pCR) (n=67) – 10.3%
•  Partial Response (n=233)   
•  No response (n=349) 
Excluded from analysis (n=1893) 
♦  No chemoradiotherapy (n=1611) 
♦  Short course radiotherapy (n = 177)
♦  Palliative chemotherapy (n=86)
♦  Missing adjuvant therapy data (n=28) 
♦  Missing response data (n=30)Included in analysisNeoadjuvant 
therapy
Patients undergoing cancer surgery (n=2579) 
Excluded from analysis (n=507) 
♦  Benign disease (n=500)
Figure 1 Flowchart for patients included in the analysis of pre-operative chemoradiotherapy followed by elective rectal cancer
surgery.
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tumours (14.5% vs 9.7%), although this association was
non-significant (T3/T4; OR: 0.64, 0.34–1.30,
P = 0.19). Despite trends towards a higher pCR rate in
low or middle rectal disease, neither tumour height
(Low rectum; OR: 1.82, 0.765.43, P = 0.22, Middle
rectum; OR: 1.64, 0.655.02, P = 0.33) or EMVI sta-
tus (EMVI positive; OR: 1.26, 0.42–3.07, P = 0.64)
were significantly associated with complete response.
Node positivity at baseline was significantly associated
with a lower rate of pCR (OR: 0.40, 0.17–0.81,
P = 0.02).
The pathology data is also summarised in Table 2.
There was no tumour in the pCR group and therefore
the grade of differentiation could not be determined,
however there was no difference in the tumour grade for
partial and non-responders. Non-responders were signifi-
cantly more likely than partial responders to be ypEMVI
positive (12.9% [30/233] vs 24.4% [85/349],
P < 0.001). The overall pCRM rate was 6.2% [40/649].
The post-CRT MRI staging (n = 429) is compared
with pathology staging in Table 3. Overall understaging
occurred in 14% (61/429) and 12.8% (55/429) of ypT
Table 1 Characteristics of patients undergoing long course neoadjuvant chemoradiotherapy.
Factor Level Total %
Pathological assessment of response to CRT
Complete (%) Partial (%) None (%) P-value
649 100.0 67 (10.3) 233 (35.9) 349 (53.8)
Patient and disease factors
Age < 55 131 20.2 12 (17.9) 44 (18.9) 75 (21.5) 0.61
55–70 308 47.5 29 (43.3) 120 (51.5) 159 (45.6)
70–80 182 28.0 24 (35.8) 60 (25.8) 98 (28.1)
> 80 28 4.3 2 (3.0) 9 (3.9) 17 (4.9)
Gender Female 229 35.3 24 (35.8) 88 (37.8) 117 (33.5) 0.57
Male 420 64.7 43 (64.2) 145 (62.2) 232 (66.5)
ASA class Low risk (ASA 1–2) 464 71.5 48 (71.6) 171 (73.4) 245 (70.2) 0.16
High risk (ASA 3–5) 178 27.4 17 (25.4) 58 (24.9) 103 (29.5)
Missing 7 1.1 2 (3.0) 4 (1.7) 1 (0.3)
BMI Normal weight 237 36.5 21 (31.3) 87 (37.3) 129 (37.0) 0.67
Underweight 16 2.5 0 (0.0) 7 (3.0) 9 (2.6)
Overweight 243 37.4 28 (41.8) 85 (36.5) 130 (37.2)
Obese 143 22.0 16 (23.9) 49 (21.0) 78 (22.3)
Missing 10 1.5 2 (3.0) 5 (2.1) 3 (0.9)
Tumour height
(measured from
anal margin) (cm)
High rectum 77 11.9 5 (7.5) 24 (10.3) 48 (13.8) 0.37
Middle rectum 225 34.7 23 (34.3) 77 (33.0) 125 (35.8)
Low rectum 347 53.5 39 (58.2) 132 (56.7) 176 (50.4)
Tumour height (cm) Mean (SD) 3.2 (1.7) 3.7 (2.1) 4.5 (3.5) 0.007
Operation factors
Operative approach Open 268 41.3 16 (23.9) 96 (41.2) 156 (44.7) < 0.001
Laparoscopic 333 51.3 38 (56.7) 127 (54.5) 168 (48.1)
Robotic 48 7.4 13 (19.4) 10 (4.3) 25 (7.2)
Duration (minutes) Mean (SD) 262.8 (97.5) 243.7 (95.8) 246.3 (97.2) 0.24
Approach Anterior Resection 424 65.3 49 (73.1) 154 (66.1) 221 (63.3) 0.04
Hartmanns 37 5.7 5 (7.5) 5 (2.1) 27 (7.7)
APE 121 18.6 7 (10.4) 45 (19.3) 69 (19.8)
ELAPE 67 10.3 6 (9.0) 29 (12.4) 32 (9.2)
Defunctioning stoma Yes 345 53.2 42 (62.7) 129 (55.4) 174 (49.9) 0.11
No 304 46.8 25 (37.3) 104 (44.6) 175 (50.1)
Outcomes
Complication grade None 364 56.1 38 (56.7) 135 (57.9) 191 (54.7) 0.75
Grade 1–2 190 29.3 18 (26.9) 67 (28.8) 105 (30.1)
Grade 3–5 92 14.2 11 (16.4) 31 (13.3) 50 (14.3)
Missing 3 0.5 0 (0.0) 0 (0.0) 3 (0.9)
CRT, chemoradiotherapy. Pathological assessment of response to CRT: complete response (ypT0,N0, EMVI-ve). Partial response
(regression from baseline MRI T stage), none (no change or progression from baseline MRI T stage).
Colorectal Disease ª 2018 The Association of Coloproctology of Great Britain and Ireland. 20 (Suppl. 6), 58–6862
Safe deferral of rectal cancer surgery The 2017 European Society of Coloproctology (ESCP) collaborating group
Table 2 Magnetic resonance imaging and pathological staging of included patients.
Factor Level Total %
Pathological Assessment of Response to CRT
Complete (%) Partial (%) None (%) P-value
649 100.0 67 (10.3) 233 (35.9) 349 (53.8)
Pre-treatment MRI staging
mrT T1 8 1.2 0 (0.0) 0 (0.0) 8 (2.3) < 0.001
T2 75 11.6 12 (17.9) 11 (4.7) 52 (14.9)
T3 479 73.8 52 (77.6) 167 (71.7) 260 (74.5)
T4 87 13.4 3 (4.5) 55 (23.6) 29 (8.3)
mrN N0 497 76.6 59 (88.1) 141 (60.5) 294 (84.2) < 0.001
N1 89 13.7 3 (4.5) 55 (23.6) 31 (8.9)
N2 66 10.2 5 (7.5) 37 (15.9) 24 (6.9)
mrEMVI No 561 86.4 58 (86.6) 194 (83.3) 309 (88.5) 0.389
Yes 40 6.2 5 (7.5) 16 (6.9) 19 (5.4)
Missing 48 7.4 4 (6.0) 23 (9.9) 21 (6.0)
mrAJCC Stage 1 58 8.9 10 (14.9) 0 (0.0) 48 (13.8) < 0.001
Stage 2 408 62.9 43 (64.2) 119 (51.1) 246 (70.5)
Stage 3 121 18.6 7 (10.4) 65 (27.9) 49 (14.0)
Stage 4 62 9.6 7 (10.4) 49 (21.0) 6 (1.7)
Post-treatment MRI re-staging
Post treatment MRI performed Yes 429 66.1 39 (58.2) 164 (70.4) 226 (64.8) 2.12
No 220 33.9 28 (41.8) 69 (29.6) 123 (35.2)
Of those restaged (n = 429) T0/1 33 7.7 8 (20.5) 13 (7.9) 12 (5.3) < 0.001
ymrT T2 107 24.9 14 (35.9) 37 (22.6) 56 (24.8)
T3 226 52.7 14 (35.9) 78 (47.6) 134 (59.3)
T4 63 14.7 3 (7.7) 36 (22.0) 24 (10.6)
ymrN N0 229 53.4 27 (69.2) 102 (62.2) 100 (44.2) < 0.001
N1 141 32.9 11 (28.2) 40 (24.4) 90 (39.8)
N2 59 13.8 1 (2.6) 22 (13.4) 36 (15.9)
ymrEMVI No 346 80.7 35 (89.7) 133 (81.1) 178 (78.8) 0.376
Yes 67 15.6 3 (7.7) 23 (14.0) 41 (18.1)
Missing 14 3.3 1 (2.6) 7 (4.3) 6 (2.7)
ymr AJCC stage Stage 1 99 23.1 16 (41.0) 41 (25.0) 42 (18.6) < 0.001
Stage 2 115 26.8 11 (28.2) 59 (36.0) 45 (19.9)
Stage 3 170 39.6 12 (30.8) 61 (37.2) 97 (42.9)
Stage 4 44 10.3 0 (0.0) 2 (1.2) 42 (18.6)
Missing 1 0.2 0 (0.0) 1 (0.6) 0 (0.0)
Post-operative pathological staging
ypT stage T0 77 11.9 67 (100.0) 2 (0.9) 8 (2.3) < 0.001
T1 34 5.2 0 (0.0) 28 (12.0) 6 (1.7)
T2 181 27.9 0 (0.0) 121 (51.9) 60 (17.2)
T3 310 47.8 0 (0.0) 67 (28.8) 243 (69.6)
T4 47 7.2 0 (0.0) 15 (6.4) 32 (9.2)
ypN stage N0 431 66.4 67 (100.0) 212 (91.0) 152 (43.6) < 0.001
N1 150 23.1 0 (0.0) 15 (6.4) 135 (38.7)
N2 68 10.5 0 (0.0) 6 (2.6) 62 (17.8)
ypEMVI No 534 82.3 67 (100.0) 203 (87.1) 264 (75.6) < 0.001
Yes 115 17.7 0 (0.0) 30 (12.9) 85 (24.4)
Differentiation grade Poor 72 11.1 – 27 (11.6) 45 (12.9) < 0.001
Moderate 337 51.9 – 128 (54.9) 209 (59.9)
Well 161 24.8 – 75 (32.2)86 (24.6)
Missing 79 12.2 67 3 9
Prefix notations: mr, MRI staging; p, pathology staging; y, staging following chemoradiotherapy (CRT). ymr, MRI staging follow-
ing CRT; AJCC, American Joint Committee on Cancer; EMVI, extramural vascular invasion; N, node; T, tumour.
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stage and ypAJCC grade cancers respectively. Overstag-
ing was reported in 35% (151/429) of ypT staging and
34% (148/429) of ypAJCC grading. Table 4 shows that
the agreement between the post-treatment MRI and
Pathology was graded ‘fair’ for T stage, N stage and
AJCC status (Kappa 0.25, 0.26 and 0.35 respectively).
Figure 2 Differences in treatment response by tumour height.
Table 3 Comparison of post-treatment MRI and pathological staging. A post-treatment MRI was performed in 66.1% (429/649)
cases. Under-staging (blue) indicated lower staging by post-treatment MRI than by pathology. Overstaging (yellow) indicated
higher staging by post-treatment MRI than by pathology.
MRI tumor classification pT0/1 pT2 pT3 pT4 Total (n) Over staged, % Under staged, % Accuracy, %
Pathologic tumor classification – yT stage
rT0/T1 14 5 6 0 25 - 44 56
rT2 21 44 30 1 96 22 32 46
rT3 14 57 129 14 214 33 7 60
rT4 3 8 31 16 58 72 – 28
Total (n) 52 114 196 31 393 34 14 52
MRI tumor classification pN0 pN1 pN2 Total (n) Over staged, % Under staged, % Accuracy, %
Pathologic tumor classification – yN stage
rN0 167 32 8 207 – 19 81
rN1 65 46 22 133 49 16 35
rN2 21 15 17 53 68 – 32
Total (n) 253 93 47 393 26 16 58
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Discussion
This large, prospective international audit identified a
pCR rate of 10.3% for patients with rectal cancer trea-
ted with preoperative chemoradiotherapy. This data was
simultaneously collected from 262 units over a period
of six weeks. It provides a unique and truly generalised
‘snapshot’ of the pathological response rate in current
practice. Many regard a pathological response as a
mixed blessing; on the one hand this reflects a favour-
able prognosis but on the other it may indicate an
unnecessary operation with the sequelae that can follow.
Consequently, there is increasing interest in trying to
identify a complete response after chemoradiotherapy
on clinical and radiological (cCR) grounds rather than
by pathological assessment (pCR). However, this ‘real-
world’ MRI staging data gives us an indication that if
current basic staging tools are used in isolation, they
will be inadequate for accurately identifying and safely
monitoring ‘deferral of surgery’ patients.
The pCR rate reported in this study is consistent
with outcomes reported in large trials that used single
agent concomitant chemotherapy and a radiotherapy
dose of at least 45 Gy. The FFCD 9203, EORTC
22921 and the German Rectal Cancer Study (CAO/
ARO/AIO-94) trials have been described extensively
elsewhere [24–26]. In summary these trials recruited
cT3 or resectable cT4M0 adenocarcinoma of the rec-
tum, located within 15, 15 and 16 cm from the anal
verge respectively [24–26]. These trials reported pCR
rates with pre-operative CRT of 11.4%, 14% and 8%
respectively [24–26]. One review of phase II and III
studies identified pCR rates ranging from 0–67% with
an overall pCR rate of 13.5% [27].
This current study identified that a pCR was associ-
ated with a lower tumour height. This finding has been
reported previously and authors postulate that lower
tumours are fixed by the pelvic floor muscles allowing
radiotherapy to be delivered more consistently which
allows for a favourable response rate [28]. A significantly
higher proportion of patients in the pCR group had a
node negative tumour at baseline. As authors have
previously discussed, this may indicate that earlier stage
tumours are more likely to produce a complete clinical
response or this may reflect a more biologically indolent
tumour that is more likely to respond favourably to
treatment [15,28,29]. The size of the tumour may also
influence complete response rates [29], however in this
study tumours were predominately mrT3 and the MRI
baseline staging suggested CRT was given in order to
downstage locally advanced tumours rather than to
achieve a complete response in early stage tumours.
Other factors previously shown to be associated with
an increased response rate include dual concomitant
chemotherapy [27], induction chemotherapy [30], con-
solidation chemotherapy [31,32], allowing time for
regression between CRT and surgery [33], and intensi-
fied pre-operative radiotherapy [17]. The pathological
assessment can also influence the pCR rate. The more
thorough the histopathology technician and the pathol-
ogist, the less likely they are to find a pCR. However
recent guidelines for assessing post-CRT rectal cancer
specimens provide recommendations on the number of
levels that should be cut from each tumour block.
These recommendations are likely to standardise the
pathological assessment of response [34].
When the response to CRT is favourable and a pCR
is achieved it can be regarded as an encouraging out-
come. Many patients with a pCR will be reassured by
the absence of a cancer. Furthermore, the longterm
outcomes are highly favourable; the German Rectal
Cancer trial reported a 10 year DFS of 89.5% with a
pCR, compared with 63% when minimal tumour regres-
sion occurred (p = 0.008) [35]. On the other hand this
represents a missed opportunity for organ preservation.
In selected patients it is possible to avoid surgery. Thus
much of the morbidity may be prevented along with
the reported 90-day post-operative mortality of 4–5%
[4]. Deferral of surgery has now been reported for 867
patients from 23 studies [13]. In highly selected cases,
motivated centres with established surveillance protocols
report no significant difference between ‘deferral of sur-
gery’ for a cCR compared with surgery for a pCR [13].
They found no difference in non-regrowth recurrence
Table 4 Agreement between post-treatment MRI and pathological staging.
Pathological stage
ymr v pathology
Agreement (%) Agreement (Kappa) Kappa P-value Intraclass correlation coefficient
ypT-stage 50.7 0.249 < 0.001 0.26 (0.09–0.84)
ypN-stage 58.8 0.264 < 0.001 0.25 (0.08–0.93)
ypAJCC stage 52.8 0.348 < 0.001 0.35 (0.14–0.88)
Agreement refers to the concordance of post-treatment MRI re-staging with pathological staging.
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(RR 0.58, 95% CI 0.18–1.90), disease-free survival (HR
0.56, 95% CI 0.20–1.60), or overall survival (HR 3.91,
95% CI 0.57–26.72) [13].
The challenge that currently prevents widespread
uptake of ‘deferral of surgery’ is the inability to reliably
identify and monitor responders. In our study ‘fair’
Kappa agreements of 0.25, 0.26 and 0.35 were reported
for ypT stage, ypN stage and ypAJCC grade respectively
with understaging occurred in over 10% of cases and
overstaging in over 30% of cases. These Kappa agree-
ments exceed published agreements for other methods of
assessing response such as mrRECIST [Response Evalua-
tion Criteria In Solid Tumors] criteria and MR volumetric
analysis (Kappa 0.12 and 0.36 respectively) [36]. How-
ever higher Kappa agreement scores of > 0.4 have been
reported for ymr versus pT stage assessment in selected
centres [36]. Nevertheless, these data suggests that the
techniques used in a typical international surgical unit for
post-treatment MRI staging are insufficiently reliable to
allow for the safe delivery of deferral of surgery.
In selected centres, multidisciplinary team (MDT) ori-
entated standardised protocols have contributed to sig-
nificant improvements in the interpretation of response
to chemoradiotherapy; multimodal assessment, with T2
weighted-MRI serving as the primary screening tool, in
conjunction with clinical and endoscopic examination, is
used to evaluate response [37–39]. This suggests that
with optimal training and experience, current tools can
be used effectively to select patients whose tumours have
responded favourably to chemoradiotherapy. Neverthe-
less in a global setting we share the view of the authors of
the MERRION study [40] and Putte et al. who sug-
gested current imaging modalities have a low accuracy for
predicting a true pathological complete response, indicat-
ing that deferral of surgery should not be offered outside
of well-designed clincal trials [41]. Whilst we need to
search for alternative methods for assessing response.
The actively recruiting TRIGGER randomised con-
trol trial is testing methods to identify, and safely moni-
tor, clinical complete responders [42]. The trial, uses
current MRI imaging in a smarter way, to identify clini-
cal complete responders by applying a 5-point MRI
tumour regression grade (mrTRG), which most closely
resembles the Mandard pathologic TRG system [39].
The basic principle of both grading systems relate to
the ratio of tumour to fibrosis following CRT. This is
the first imaging technique that has been shown to
assess the degree of tumour regression and to correlate
the findings with pathology and with long-term survival
[37,43]. A unique aspect of this trial is that participat-
ing units are trained to report mrTRG and may only
take part when the unit radiologist completes a training
dataset for mrTRG and achieves a high degree of
agreement with the index radiologist (Kappa ≥ 0.7)
[42]. TRIGGER may enable the dissemination of a
standardised, reliable, evidence based technique for
assessing post-chemoradiotherapy response.
There are a number of limitations with this study.
There is a lack of detail in terms of treatment approach.
We did not know the exact radiotherapy dose used,
whether pre-operative ‘consolidation’ or ‘induction’ sys-
temic chemotherapy was used in addition to CRT or
the standard waiting time between completion of CRT
(or short course radiotherapy) and surgery. Conse-
quently we have not been able to perform a multivariate
analysis to explore the key risk factors for predicting a
favourable response to CRT. Although it was compul-
sory for data to be reviewed by a senior member of the
department prior to submission, no external audit of
the radiology or pathology was performed and we could
not be certain that recogised standardised methods were
performed [34,42]. For the purposes of this study we
believe this to be acceptable because it simply reflects
the ‘real-world’ data that we aimed to assess. Finally,
only patients undergoing surgery were included in the
study. It is possible that a number of units already prac-
tice deferral of surgery. However, for the reasons out-
lined above we would recommend that this is
performed within the context of a clinical trial.
Conclusions
The pathological complete response (pCR) rate of 10%
reported in this international audit is consistent with rates
reported in clinical trials that used concomitant chemora-
diotherapy. This highlights the potential for non-opera-
tive management in selected rectal cancer patients,
however the number of eligible patients may be increased
if treatment strategies that enhance the overall response
rate are pursued. The second barrier to non-operative
management is the limited strength of agreement
between post-CRT imaging and pathology. This suggests
that assessing response with crude measures such as post-
treatment T stage and post-treatment AJCC grade are
not reliable or generalisable. Alternative detection meth-
ods, such as mrTRG with serial assessment, need to be
considered in the context of clinical trials in order to fea-
sibly allow safe widespread uptake of deferral of surgery.
Acknowledgements
Supported by the European Society of Coloproctology
(ESCP). REDCap and infrastructural support was
received from the Birmingham Surgical Trials Institute
(BiSTC) at the Birmingham Clinical Trials Unit
(BCTU).
Colorectal Disease ª 2018 The Association of Coloproctology of Great Britain and Ireland. 20 (Suppl. 6), 58–6866
Safe deferral of rectal cancer surgery The 2017 European Society of Coloproctology (ESCP) collaborating group
Conflicts of interest
None to declare.
Funding
None.
References
1 Ferlay J, Soerjomataram I, Dikshit R et al. Cancer inci-
dence and mortality worldwide: Sources, methods and
major patterns in GLOBOCAN 2012. Int J Cancer 2015;
136: E359–86.
2 Braun K, Hill J, Kuryba A et al. National Bowel Cancer
Audit: Annual Report 2016. 2016 https://www.hqip.org.
uk/wp-content/uploads/2018/02/national-bowel-cancer-
audit-annual-report-2016.pdf
3 Heald RJ, Ryall RD. Recurrence and survival after total
mesorectal excision for rectal cancer. Lancet 1986; 1:
1479–82.
4 van der Sijp MP, Bastiaannet E, Mesker WE et al. Differ-
ences between colon and rectal cancer in complications,
short-term survival and recurrences. Int J Colorectal Dis
2016; 31: 1683–91.
5 Battersby NJ, Juul T, Christensen P et al. Predicting the
risk of bowel-related quality-of-life impairment after
restorative resection for rectal cancer: a multicenter cross-
sectional study. Dis Colon Rectum 2016; 59: 270–80.
6 Bryant CL, Lunniss PJ, Knowles CH, Thaha MA, Chan
CL. Anterior resection syndrome. Lancet Oncol. 2012; 13:
e403–8.
7 Vonk-Klaassen SM, de Vocht HM, den Ouden ME, Eddes
EH, Schuurmans MJ. Ostomy-related problems and their
impact on quality of life of colorectal cancer ostomates: a
systematic review. Qual Life Res 2016; 25: 125–33.
8 Lange MM, van de Velde CJ. Urinary and sexual dysfunction
after rectal cancer treatment.Nat Rev Urol 2011; 8: 51–7.
9 Bach SP, Hill J, Monson JR et al. A predictive model for
local recurrence after transanal endoscopic microsurgery for
rectal cancer. Br J Surg 2009; 96: 280–90.
10 Habr-Gama A, Perez RO, Nadalin W et al. Operative ver-
sus nonoperative treatment for stage 0 distal rectal cancer
following chemoradiation therapy: long-term results. Ann
Surg 2004; 240: 711–7; discussion 7–8.
11 Habr-Gama A. Nonoperative management of distal rectal
cancer after chemoradiation: experience with the “Watch &
Wait” protocol. In: Rectal Cancer - A Multidisciplinary
Approach to Management (ed. Santoro GA). Sao Paulo:
InTech, 2011. pp. 317–336.
12 Maas M, Beets-Tan RG, Lambregts DM et al. Wait-and-
see policy for clinical complete responders after chemoradi-
ation for rectal cancer. J Clin Oncol 2011; 29: 4633–40.
13 Dossa F, Chesney TR, Acuna SA, Baxter NN. A watch-
and-wait approach for locally advanced rectal cancer after
a clinical complete response following neoadjuvant
chemoradiation: a systematic review and meta-analysis.
Lancet Gastroenterol Hepatol 2017; 2: 501–13.
14 Renehan AG, Malcomson L, Emsley R et al. Watch-and-
wait approach versus surgical resection after chemoradio-
therapy for patients with rectal cancer (the OnCoRe pro-
ject): a propensity-score matched cohort analysis. Lancet
Oncol 2016; 17: 174–83.
15 Dattani M, Heald RJ, Goussous G et al. Oncological and
survival outcomes in watch and wait patients with a clinical
complete response after neoadjuvant chemoradiotherapy
for rectal cancer: a systematic review and pooled analysis.
Ann Surg 2018; [Epub ahead of print]
16 Habr-Gama A, Sabbaga J, Gama-Rodrigues J et al. Watch
and wait approach following extended neoadjuvant
chemoradiation for distal rectal cancer: are we getting clo-
ser to anal cancer management? Dis Colon Rectum 2013;
56: 1109–17.
17 Appelt AL, Ploen J, Harling H et al. High-dose chemora-
diotherapy and watchful waiting for distal rectal cancer: a
prospective observational study. Lancet Oncol 2015; 16:
919–27.
18 Sobin LH, Compton CC. TNM seventh edition: what’s
new, what’s changed: communication from the Interna-
tional Union Against Cancer and the American Joint Com-
mittee on Cancer. Cancer 2010; 116: 5336–9.
19 Bonnetain F, Bosset JF, Gerard JP et al. What is the clini-
cal benefit of preoperative chemoradiotherapy with 5FU/
leucovorin for T3-4 rectal cancer in a pooled analysis of
EORTC 22921 and FFCD 9203 trials: surrogacy in ques-
tion? Eur J Cancer 2012; 48: 1781–90.
20 von Elm E, Altman DG, Egger M et al. Strengthening the
Reporting of Observational Studies in Epidemiology
(STROBE) statement: guidelines for reporting observa-
tional studies. BMJ 2007; 335: 806–8.
21 Altman DG. Practical Statistics for Medical Research. Lon-
don: Chapman & Hall/CRC, 1991.
22 Thomas JD, Hultquist RA. Interval estimation for the
unbalanced case of the one-way random effects model.
Ann Stat 1978; 6: 582–7.
23 Donner A. The use of correlation and regression in the
analysis of family resemblance. Am J Epidemiol 1979; 110:
335–42.
24 Bosset JF, Collette L, Calais G et al. Chemotherapy with
preoperative radiotherapy in rectal cancer. N Engl J Med
2006; 355: 1114–23.
25 Gerard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I,
Hennequin C, Etienne PL, et al. Comparison of two neoad-
juvant chemoradiotherapy regimens for locally advanced rec-
tal cancer: results of the phase III trial ACCORD 12/0405-
Prodige 2. J Clin Oncol 2010; 28: 1638–44.
26 Sauer R, Becker H, Hohenberger W et al. Preoperative ver-
sus postoperative chemoradiotherapy for rectal cancer. N
Engl J Med 2004; 351: 1731–40.
27 Hartley A, Ho KF, McConkey C, Geh JI. Pathological
complete response following pre-operative chemoradiother-
apy in rectal cancer: analysis of phase II/III trials. Br J
Radiol 2005; 78: 934–8.
Colorectal Disease ª 2018 The Association of Coloproctology of Great Britain and Ireland. 20 (Suppl. 6), 58–68 67
The 2017 European Society of Coloproctology (ESCP) collaborating group Safe deferral of rectal cancer surgery
28 Yu SK, Tait D, Chau I, Brown G. MRI predictive factors
for tumor response in rectal cancer following neoadjuvant
chemoradiation therapy–implications for induction
chemotherapy? Int J Radiat Oncol Biol Phys 2013; 87:
505–11.
29 Habr-Gama A, Perez RO, Sabbaga J, Nadalin W, Sao
Juliao GP, Gama-Rodrigues J. Increasing the rates of com-
plete response to neoadjuvant chemoradiotherapy for distal
rectal cancer: results of a prospective study using additional
chemotherapy during the resting period. Dis Colon Rectum
2009; 52: 1927–34.
30 Chua YJ, Barbachano Y, Cunningham D et al. Neoadjuvant
capecitabine and oxaliplatin before chemoradiotherapy and
total mesorectal excision in MRI-defined poor-risk rectal
cancer: a phase 2 trial. Lancet Oncol 2010; 11: 241–8.
31 Caravatta L, Picardi V, Tambaro R et al. Neoadjuvant
accelerated concomitant boost radiotherapy and multidrug
chemotherapy in locally advanced rectal cancer: a dose-
escalation study. Am J Clin Oncol 2012; 35: 424–31.
32 Garcia-Aguilar J, Renfro LA, Chow OS et al. Organ preser-
vation for clinical T2N0 distal rectal cancer using neoadju-
vant chemoradiotherapy and local excision (ACOSOG
Z6041): results of an open-label, single-arm, multi-institu-
tional, phase 2 trial. Lancet Oncol 2015; 16: 1537–46.
33 Gollins S, Moran B, Adams R et al. Association of Colo-
proctology of Great Britain & Ireland (ACPGBI): Guideli-
nes for the Management of Cancer of the Colon, Rectum
and Anus (2017) – Multidisciplinary Management. Colorec-
tal Dis 2017; 19: 37–66.
34 Loughrey MB, Quirke P, Shepherd NA. Data set for
Colorectal Cancer Histopathology Reports, 2017. http://
www.rcpath.org/Resources/RCPath/ (accessed May 2018).
35 Fokas E, Liersch T, Fietkau R et al. Tumor regression grad-
ing after preoperative chemoradiotherapy for locally
advanced rectal carcinoma revisited: updated results of the
CAO/ARO/AIO-94 trial. J Clin Oncol 2014; 32: 1554–62.
36 Patel UB, Brown G, Rutten H et al. Comparison of mag-
netic resonance imaging and histopathological response to
chemoradiotherapy in locally advanced rectal cancer. Ann
Surg Oncol 2012; 19: 2842–52.
37 Bhoday J, Smith F, Siddiqui MR et al. Magnetic resonance
tumor regression grade and residual mucosal abnormality
as predictors for pathological complete response in rectal
cancer postneoadjuvant chemoradiotherapy. Dis Colon Rec-
tum 2016; 59: 925–33.
38 Maas M, Lambregts DM, Nelemans PJ et al. Assessment of
clinical complete response after chemoradiation for rectal
cancer with digital rectal examination, endoscopy, and
MRI: selection for organ-saving treatment. Ann Surg Oncol
2015; 22: 3873–80.
39 Patel UB, Blomqvist LK, Taylor F et al. MRI after treat-
ment of locally advanced rectal cancer: how to report
tumor response–the MERCURY experience. AJR Am J
Roentgenol 2012; 199: W486–95.
40 Hanly AM, Ryan EM, Rogers AC et al. Multicenter Evalu-
ation of Rectal cancer ReImaging pOst Neoadjuvant
(MERRION) therapy. Ann Surg 2014; 259: 723–7.
41 Putte DV, Nieuwenhove YV, Willaert W, Pattyn P, Ceelen
W. Organ preservation in rectal cancer: current status and
future perspectives. Colorectal. Cancer 2015; 4: 185–97.
42 Battersby NJ, Dattani M, Rao S et al. A rectal cancer feasi-
bility study with an embedded phase III trial design assess-
ing magnetic resonance tumour regression grade (mrTRG)
as a novel biomarker to stratify management by good and
poor response to chemoradiotherapy (TRIGGER): study
protocol for a randomised controlled trial. Trials 2017; 18:
394. See Appendix 6 of the protocol for a standardised
method of performing the MRI.
43 Patel UB, Taylor F, Blomqvist L et al. Magnetic resonance
imaging-detected tumor response for locally advanced rec-
tal cancer predicts survival outcomes: MERCURY experi-
ence. J Clin Oncol 2011; 29: 3753–60.
Authorship list
Writing group
Nick Battersby (Chair), James C. Glasbey, Peter Neary,
Ionut Negoi, Sivesh Kamarajah, Alessandro Sgro, Dmi-
tri Nepogodiev, Aneel Bhangu, Thomas Pinkney, Mat-
teo Frasson.
ESCP cohort studies and audits committee
Alaa El-Hussuna (2017 Audit Lead), Nick J. Battersby,
Aneel Bhangu, Nicolas C. Buchs, Christianne Buskens,
Sanjay Chaudri, Matteo Frasson, Gaetano Gallo, James
Glasbey, Ana Marıa Minaya-Bravo, Dion Morton, Ionut
Negoi, Dmitri Nepogodiev, Francesco Pata, Tomas
Poskus, Luis Sanchez-Guillen, Baljit Singh, Oded
Zmora, Thomas Pinkney (Chair).
Statistical analysis and data management
James Glasbey, Dmitri Nepogodiev, Rita Perry, Laura
Magill, Aneel Bhangu (Guarantor).
ESCP research committee
Dion Morton (Chair), Donato Altomare, Willem
Bemelman, Steven Brown, Christianne Buskens, Quen-
tin Denost, Charles Knowles, Søren Laurberg, Jeremie
H. Lefevre, Gabriela M€oeslein, Tom Pinkney, Caro-
lynne Vaizey, Oded Zmora.
Collaborators
See page 27–32 for full print list. All collaborating
authors will be listed in the online edition, and be
PubMed citable.
Colorectal Disease ª 2018 The Association of Coloproctology of Great Britain and Ireland. 20 (Suppl. 6), 58–6868
Safe deferral of rectal cancer surgery The 2017 European Society of Coloproctology (ESCP) collaborating group
